[PDF] Top 20 Relación Entre La Responsabilidad Social Corporativa Y Las Multinacionales
Has 10000 "Relación Entre La Responsabilidad Social Corporativa Y Las Multinacionales" found on our website. Below are the top 20 most common "Relación Entre La Responsabilidad Social Corporativa Y Las Multinacionales".
<p>Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain</p>
... When comparing two potentially curative interven- tions, and in line with the recommendations of pharma- coeconomic guidelines, our study adopted a lifetime time horizon. The availability of long-term overall survival ... See full document
20
Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
... agent and cytarabine, is followed by consolidation chem- otherapy, typically consisting of high-dose cytarabine, in patients who achieve complete remission (CR). Patients may also receive post-remission maintenance ... See full document
10
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
... of FLT3 mutations in only a subset of AML cells suggests that they may be disease promoting as opposed to ...mutant FLT3-mediated signaling may contribute to leukemic cell survival even in the presence of ... See full document
9
Midostaurin: an emerging treatment for acute myeloid leukemia patients
... inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combi- nation with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) ... See full document
37
Clinical use of FLT3 inhibitors in acute myeloid leukemia
... Abstract: Acute myeloid leukemia (AML) is a highly heterogeneous ...disease. Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most ... See full document
5
<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>
... is midostaurin (PKC-412, Novartis), a multi-kinase inhibitor with activity against both FLT3- ITD and FLT3-TKD (type 1 ...generation FLT3 inhibitor, the clinical development of ... See full document
9
FLT3 inhibitors in acute myeloid leukemia
... both FLT3/ITD and re- sistant FLT3/D835 mutants in patients with AML ...diagnosed FLT3 mutant AML ...with FLT3/ITD and 3 patients with FLT3/D835 ...with FLT3-mutated AML [63]. A ... See full document
165
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
... drug treatment methods for AML include chemotherapy, targeted therapy, and ...as FLT3 and IDH. In FLT3-mutated group, first-generation agents such as sorafenib, lestaurtinib, midostaurin, ... See full document
14
<p>Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection</p>
... As FLT3 inhibitors are more frequently being used in FLT3-mutated AML, the role of stem cell transplant needs to be better de fi ...received midostaurin with induction/consolidation and then underwent ... See full document
180
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
... of FLT3/ITD and TKD mutations ...chronic myeloid leukemia and myeloproliferative neoplasms [18–21]. FLT3/ITD and FLT3/TKD are ideal targets for small molecule ...Multiple FLT3 ... See full document
25
Structural and functional Alterations of FLT3 in Acute Myeloid Leukemia
... of FLT3/ALM in pediatric and adult AML. Prevalence of FLT3/ALM is 6-8%, regardless of age and the presence of FLT3/ALM and FLT3/ITD appears to be mutually ...of FLT3/ALM is not ... See full document
168
FLT3 inhibitors: clinical potential in acute myeloid leukemia
... Abstract: Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%–40% of ...of leukemia cell ...the FLT3 gene are the ones most commonly ... See full document
98
Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
... Third, due to limited patients included and various responses to different FLT3 inhibitor therapies, results of these stud- ies were inconclusive, leading to relatively large CIs of our pooled analysis. More ... See full document
55
<p>Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia</p>
... The IDH1/2 genes encode tumor-suppressor proteins IDH1/2 whose mutations appear to induce DNA hypermethylation at speci fi c sequences. About 15 – 20% of all AML subtypes and 25 – 30% of CN-AML subtype harbor IDH1/2 ... See full document
67
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress
... concurrent treatment with Pim kinase inhibitor and topoisomerase 2 inhibitors on growth of Ba/F3-ITD cells was cytotoxic or cytostatic, effects on cell cycle and on induction of apoptosis were ... See full document
113
Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
... Notes: simulated patients can transit between disease states in the direction shown by the arrow. “Fractured” is a temporary state and denotes patients with an existing osteoporotic hip, vertebral, or wrist fracture. All ... See full document
17
<p>Acute myeloid leukemia patient with <em>FLT3-ITD</em> and <em>NPM1</em> double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis </p>
... HL is de fi ned as the WBC count above 100,000/mm 3 in peripheral blood at the initial diagnosis. In this study, the proportion of patients with HL at initial diagnosis of AML FLT3-ITD+/NPM1+ patients accounted for ... See full document
33
<p>Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia</p>
... the treatment-naïve ...of treatment, 21% of patients responded to venetoclax plus either low-dose cytarabine, decitabine, or azacitidine; median OS was 3 months among the entire cohort, and ... See full document
79
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
... of leukemia and human AML cells [8, 9], and therefore represent important therapeutic ...targeting FLT3 have been investigated in clinical trials, including CEP-701, PKC412, sorafenib and ...as FLT3 ... See full document
97
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
... Daily treatment with MRX-2843 was well tolerated in mice for up to 120 ...to FLT3 inhibition, the effects of inhibitors such as quizartinib have been well described, with myelosuppression being one of the ... See full document
5
Related subjects